Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT

Bone Marrow Transplantation volume 45, pages 403–404 (2010)Cite this article

Relapse of AML after Allo-SCT is treated with one or more of the following: withdrawal of immunosuppression, salvage chemotherapy, second transplantation and donor leukocyte infusions. The outcome is usually unsatisfactory.

Treatment with the immunomodulating agent lenalidomide results in high response rates in patients with low-risk myelodysplastic syndrome with del(5)(q13q33).1 Although there are three published case reports of the successful use of lenalidomide as initial therapy for AML with del(5)(q13q33), there are no reported results of its use in relapse after transplantation; a clinical situation in which immunomodulatory agents may have unpredictable effects.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.

    Article  CAS  Google Scholar 

  2. Mesa RA, Tefferi A, Li CY, Steensma DP . Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia 2006; 20: 2063–2064.

    Article  CAS  Google Scholar 

  3. Lancet JF, List AF, Moscinski LC . Treatment of deletion 5q acute myeloid leukemia with lenalidomide. Leukemia 2007; 21: 586–588.

    Article  CAS  Google Scholar 

  4. Penarrubia MJ, Silvestre LA, Conde J, Cantalapiedra A, Garcia Frade LJ . Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion. Leuk Res 2009; 33: e8–e9.

    Article  CAS  Google Scholar 

  5. Mohty M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N et al. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myelome (IFM) and the Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005; 35: 165–169.

    Article  CAS  Google Scholar 

  6. Minnema MC, van der Veer MS, Aarts T, Emmelot M, Mutis T, Lokhorst HM . Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009; 23: 605–607.

    Article  CAS  Google Scholar 

  7. Fehniger TA, Byrd JC, Marcucci G, Abboud CN, Kefauver C, Payton JE et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009; 113: 1002–1005.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Intermountain Blood and Marrow Transplant Program, LDS Hospital, Salt Lake City, UT, USA

    C D Ford, J Asch, K Konopa & F B Petersen

Authors
  1. C D Ford
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Asch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Konopa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F B Petersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C D Ford.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ford, C., Asch, J., Konopa, K. et al. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplant 45, 403–404 (2010). https://doi.org/10.1038/bmt.2009.146

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.146

This article is cited by

Search

Advanced search

Quick links